Disease Information
General Information of the Disease (ID: DIS00529)
| Name |
Tongue cancer
|
|---|---|
| ICD |
ICD-11: 2B62
|
| Resistance Map |
Type(s) of Resistant Mechanism of This Disease
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: AMP-activated kinase alpha-2 (PRKAA2) | [1] | |||
| Metabolic Type | Glucose metabolism | |||
| Sensitive Disease | Tongue squamous cell carcinoma [ICD-11: 2B62.0] | |||
| Sensitive Drug | Capsaicin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | mTOR signaling pathway | Activation | hsa04150 | |
| AMPK signaling pathway | Activation | hsa04152 | ||
| Insulin signaling pathway | Activation | hsa04910 | ||
| In Vivo Model | Tumor xenograft model | Mice | ||
| Experiment for Drug Resistance |
Tumor weight assay | |||
| Mechanism Description | Overall, combined treatment with capsaicin and cisplatin reversed cisplatin resistance by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. | |||
| Key Molecule: AMP-activated kinase alpha-2 (PRKAA2) | [1] | |||
| Metabolic Type | Glucose metabolism | |||
| Sensitive Disease | Tongue squamous cell carcinoma [ICD-11: 2B62.0] | |||
| Sensitive Drug | Capsaicin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | mTOR signaling pathway | Activation | hsa04150 | |
| AMPK signaling pathway | Activation | hsa04152 | ||
| Insulin signaling pathway | Activation | hsa04910 | ||
| In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
| Experiment for Drug Resistance |
Cell viability assay | |||
| Mechanism Description | Overall, combined treatment with capsaicin and cisplatin reversed cisplatin resistance by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: AMP-activated kinase alpha-2 (PRKAA2) | [1] | |||
| Metabolic Type | Glucose metabolism | |||
| Resistant Disease | Tongue squamous cell carcinoma [ICD-11: 2B62.0] | |||
| Resistant Drug | Cisplatin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | mTOR signaling pathway | Activation | hsa04150 | |
| AMPK signaling pathway | Activation | hsa04152 | ||
| Insulin signaling pathway | Activation | hsa04910 | ||
| In Vivo Model | Tumor xenograft model | Mice | ||
| Experiment for Drug Resistance |
Tumor weight assay | |||
| Mechanism Description | Overall, combined treatment with capsaicin and cisplatin reversed cisplatin resistance by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. | |||
| Key Molecule: AMP-activated kinase alpha-2 (PRKAA2) | [1] | |||
| Metabolic Type | Glucose metabolism | |||
| Resistant Disease | Tongue squamous cell carcinoma [ICD-11: 2B62.0] | |||
| Resistant Drug | Cisplatin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | mTOR signaling pathway | Activation | hsa04150 | |
| AMPK signaling pathway | Activation | hsa04152 | ||
| Insulin signaling pathway | Activation | hsa04910 | ||
| In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
| Experiment for Drug Resistance |
Cell viability assay | |||
| Mechanism Description | Overall, combined treatment with capsaicin and cisplatin reversed cisplatin resistance by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis. | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
